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1. Introduction 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder, characterized 
by motor and non-motor signs. It was Charcot, who first in 1875 pointed out that ‘psychic 
faculties are definitely impaired’ and that ‘the mind becomes clouded and the memory is 
lost’. Most patients with PD experience some degree of cognitive impairment, ranging from 
mild selective deficits to Parkinson’s disease dementia (Dubois & Pillon, 1997). PD patients 
may also spend several years in a transition state called Mild Cognitive Impairment (MCI), 
which is now recognized as one of the cardinal non-motor manifestations of PD. It is a major 
cause of disability, and has been shown to be an important predictor for quality of life 
(Karlsen et al., 1998). Recent studies have reported a 21% prevalence rate of MCI in a large 
PD population and consider MCI as a risk factor for developing Parkinson’s disease 
Dementia (PDD) (Caviness et al., 2007; Janvin et al., 2006; Levin et al., 1992). The 
neuropathophysiological basis of cognitive deficits in PD is complicated and includes 
degeneration of dopaminergic neurons mainly of the nigrostriatal pathway and to a lesser 
degree the mesocortical and mesolimbic pathways. The striatum is closely interrelated to 
cortical areas mainly to the frontal lobes. The neuropathophysiological puzzle is further 
complicated by multiple neurotransmitter deficits including noradrenalin, serotonin and 
acetylcholine pathway as well as Lewy body- type degeneration in cortical and limbic 
structures (Mandir & Vaughan, 2000).  The direct dopaminergic connections between the 
ventral tegmental area and the prefrontal cortex may also influence changes in cognition 
(Cools 2006; Mattay et al., 2002).  The pattern of cognitive impairment seen even in early PD 
mainly resembles that produced by frontal lobe damage, as the basal ganglia and prefrontal 
cortex are closely interrelated through anatomofunctional circuits (Alexander et al., 1986; 
Bondi et al., 1993) and include deficits mainly in cognitive flexibility, planning, working 
memory and learning.  
Perfusion brain single photon emission computed tomography (SPECT) provides a well-
established means of studying regional cerebral blood flow (rCBF) which is known to reflect 
cortical function. On the other hand Dopamine Transporter (DAT) SPECT imaging can be 
used as a marker for the degree of loss of dopaminergic nerve endings. It is well known that 
SPECT Neuroimaging can assist in the differential diagnosis of parkinsonian and dementia 
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syndromes and DAT SCAN can also be helpful in differentiating tremors resulting from 
damage to the nigrostriatal dopaminergic terminals from those due to essential tremor, 
drug-induced or psychogenic causes (Benamer et al., 2000). SPECT can also be useful in 
monitoring disease progression as well as providing information about the 
pathophysiological process. 
Numerous studies during the last decade have attempted to investigate differences and 
associations between cortical perfusion, nigrostriatal dopamine pathway and 
neuropsychological functions in demented and non demented patients with PD. These 
studies show a tendency towards increased hypoperfusion in parietal and temporal lobes in 
PDD as compared to the non demented PD patients (Derejko et al., 2006; Liu et al., 1992; 
Matsui et al., 2005).There are also conflicting results in the literature regarding PD patients 
with MCI ranging from either no difference compared to controls (Sawada et al.,1992; 
Spampinato et al., 1991) to hypoperfusion in the parietal (Wallin et al., 2007) and frontal 
areas (Antonini et al., 2001; Firbank et al., 2005; Paschali et al., 2009). Regarding rCBF and 
neuropsychological functions in different stages of PD, as dopaminergic nerve endings 
degenerate in PD there is progressive cortical hypoperfusion affecting mainly the frontal 
lobes in the early stages, extending to the parietal and temporal lobes in the late stages of 
Parkinson’s disease. In parallel, neuropsychological performance gradually deteriorates as 
the disease progresses (Paschali et al., 2010). 
In the present chapter we will discuss neuropsychological deficits seen early in the course of 
Parkinson’s disease as well as clinical characteristics of dementia seen later in the course of 
PD. We will also discuss the underlying neurochemistry of these cognitive impairments and 
address the concept of heterogeneous nature of the observed cognitive dysfunction in PD as 
revealed by neuropsychological and neuroimaging studies with a focus on SPECT 
neuroimaging.   
2. Epidemiology of PDD 
2.1 Prevalence rates 
The prevalence of dementia in PD was reported to range from 2% in early onset cases 
(Hietanen &Teravainen, 1988) to 81% in an unselected patient population (Martin et al., 
1973). In a review of 27 studies, an average prevalence of 40% was found (Cummings JL 
1988). Other community based studies have estimated the point prevalence for dementia in 
PD to be between 28% and 44% (Mayeux et al., 1992).One longitudinal study observed a 
52% prevalence rate of dementia with over 4 years follow-up and 60% prevalence rate of 
dementia with over 12 years follow up in 233 patients with PD (Buter et al., 2008). Another 
prospective study of 249 patients with PD observed a 65% risk rate of dementia by age 85 
years (Mayeux et al., 1990). A further prospective study of 86 patients with PD and 102 age-
matched controls estimated that the relative risk for dementia was equal to 5.1 in patients 
with PD (Hobson et al., 2004). In another study conducted in the general population, the 
prevalence of dementia among patients with PD was 41% and the association with age was 
striking, i.e. the prevalence rate was zero in patients below the age of 50 and 69% in patients 
above 80 years old (Mayeux et al., 1992). The variation noted between different studies is 
probably due to different methods of cognitive assessment, how dementia was defined, the 
study populations chosen and the data collection methods. 
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2.2 Incidence rates 
Incidence studies may provide a more accurate estimate of risk of dementia in PD because 
of their prospective nature. Incidence of dementia was found to be consistently higher in 
patients with PD than in persons without PD. The number of demented patients was found 
to be four times higher than expected over a period of 3 years (Mindham et al., 1982). In 
another prospective study, the incidence of dementia was six times higher in patients with 
PD than in controls (Aarsland et al., 2001). In a survey of 83 patients and 50 controls, who 
were free of dementia at baseline, followed over 10 and 14 years, the cumulative incidence 
rate was 38% and 53% respectively (Hughes et al.,2000; Read et al.,2001).  
3. Neuropsychology of Parkinson’s disease 
3.1 Neuropsychological deficits in PD  
Cognitive deficits in PD are found early in the disease process even before initiation of anti-
parkinsonian treatment and resemble those commonly attributed to frontal lobe 
dysfunction. PD patients have been reported to have reduced cognitive speed and increased 
distractibility, problems in set formation and impairment in set shifting and maintaining, 
visuoperceptual deficits, deficits in executive functions such as self-directed planning and 
problem solving and deficits in working memory. Characteristically, Parkinson’s disease 
patients fail to solve a novel task when relying on internal rather than external cues. 
Memory impairments, mainly depicted in decreased performance in free recall tasks, while 
recognition memory appears to be intact, are thought to represent defective retrieval 
strategies, that is inability for active organization of the material to be remembered  
Dopamine restoration offers relief from many of the motor symptoms of Parkinson’s disease 
and has also been shown to exert beneficial effects on certain aspects of cognition that 
involve mainly executive functions, while memory and visuospatial deficits seem to be less 
dopamine dependent. Moreover, dopaminergic medication may have deleterious effects on 
certain cognitive functions such as reversal learning. This has led to the formation of the 
dopamine overdose hypothesis, according to which, dopamine dosing that ameliorates 
motor symptoms by restoring dopamine concentrations in severely depleted brain areas 
such as the putamen may impair some aspects of cognition by overdosing other areas, 
which are less dopaminergically depleted early in the disease such as the caudate nucleus 
and ventral striatum (Cools et al., 2001.) The pathological basis of cognitive impairments in 
PD has been attributed to disruption of the “complex loop” which connects the caudate 
nucleus with the frontal association regions, via the thalamus or to loss of dopaminergic 
neurons in the ventro-tegmental area affecting meso-cortico-limbic pathways. As cognitive 
impairment in PD however, is inadequately explained by dopamine loss alone, alternative 
hypotheses have been raised implicating the underlying frontal cholinergic denervation as 
outlined in a following section of this chapter.   
3.2 Mild cognitive impairment in PD 
Parkinson’s disease is often associated with mild cognitive impairment (MCI) and dementia. 
The term mild cognitive impairment is used in Parkinson’s disease to include diverse 
neuropsychological deficits within the executive, mnemonic and visuospatial domains. 
Cognitive impairment in a single or in multiple domain(s) is common in non-demented 
patients with PD (Foltynie et al., 2004; Janvin et al., 2003) and more than 50% of patients 
with PD will develop dementia and cognitive impairment which ultimately affects quality 
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of life (Schrag et al., 2000). The original MCI definition requires presence of subjective 
cognitive complaints (preferably by third party), objective evidence of impaired test 
performance and lack of significant functional impairment (Petersen et al.,1999).The 
following subtypes of MCI in patients with PD have been  described. Amnestic MCI-single 
domain, amnesticMCI-multiple domain, Non-amnestic MCI-Single domain and Non-
amnestic MCI-multiple domain (Aarsland D. et al,. 2010). In a study by Caviness et al., 
(2007) the majority of their patients had single domain MCI (67%), with either executive 
dysfunction (39%) or amnestic deficits (22%). Another study showed that the most prevalent 
subtypes of MCI in PD were single, non-amnestic domain (mostly executive dysfunction) in 
44,7%, followed by multiple impaired domains in 39, 5% and single amnestic domain MCI 
in 15,8% (Janvin et al., 2006). In a recently published multicenter pooled analysis study, one 
quarter of patients with Parkinson’s disease without dementia, had impairments in at least 
one cognitive domain. The most common MCI subtype was nonamnestic single domain 
(11,3%), followed by amnestic single domain MCI (8,9%).These results showed that memory 
impairment also represents an important aspect of cognitive impairment in PD, and deficits 
in attention-executive functions may not always be the predominant deficits in PD-MCI 
(Aarsland et al., 2010). Findings from the above studies, underline the necessity that 
standardized diagnostic criteria for Mild Cognitive Impairment in Parkinson’s disease need 
to be better defined. Based on existing data (Emre et al., 2004) that pharmacological 
treatment with acetylcholinesterase inhibitors can improve cognitive impairment in PDD, 
new studies must be performed in order to investigate whether these or other medications 
can delay the progression from MCI to PDD. 
3.3 Risk factors associated with development of PDD 
Several risk factors are reported to be associated with PDD. These include age at onset, age 
at the time of the study, duration of illness, akinetic-rigid syndrome, depression and atypical 
neurological features (e.g., early occurrence of autonomic nervous system failure, 
symmetrical disease presentation, and moderate response to dopaminergic treatment). More 
severe cognitive impairments and higher risk for developing dementia have also been 
associated with the clinical manifestations of postural instability and gait disorder (Alves et 
al., 2006). Further, poor performance in verbal fluency tasks was found to be significantly 
and independently associated with PDD (Jacobs et al., 1995). In summary, up to 40% of 
patients with Parkinson’s disease will develop dementia and the incidence is up to six times 
higher than aged matched controls. Older age at onset and atypical features seem to be the 
main risk factors.  With regard to neural correlates of cognitive decline in PD the hypothesis 
has been raised that this might be due to the simultaneous effect of age-related and disease 
associated neuropathology (Levy, 2007). Furthermore, it has been shown that cognitive 
status of PD patients correlates with neuropathological stage showing deterioration as the 
disease process in the brain progresses following an upward path from the brainstem to the 
neocortex (Braak et al., 2005). However, the extent of cortical alpha-synuclein pathology was 
not predictive of cognitive impairment in an autopsy series (Parkkinen et al., 2005). 
4. Clinical characteristics of PDD 
4.1 Executive function 
The phenotype of dementia associated with Parkinson’s Disease is a dysexecutive syndrome 
in which executive function (defined as the ability to plan, organize and regulate goal 
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directed behavior) impairment is the main feature (Litvan et al., 1991; Pillon et al., 1986; 
Pillon et al., 1991).These deficits include impairment in concept formation and rule finding, 
problem solving, set elaboration and planning, set shifting and set maintenance. Difficulties 
are due to shifting attention to novel stimuli, whereas preservative errors are less common 
(Levin et al., 1991).Verbal fluency has been extensively studied in PDD, where impaired 
performance is typical (Aarsland et al., 2003; Cahn-Weiner et al., 2002; Paolo et al., 1995).The 
results of these studies reveal that executive functions are impaired in PDD patients, 
probably more than in patients with AD. 
4.2 Attention  
Attention was found to be impaired in demented patients with Parkinson’s disease, as 
shown by measures of attention such as cognitive reaction and vigilance (Litvan et 
al.,1991).There were also fluctuations in attention similar to those found in patients with 
dementia with Lewy bodies (Ballard et al., 2002). In a test involving letter cancellation, it 
was found that PDD and DLB groups were slower and showed more errors than an AD 
group (Noe et al., 2004). Another study employing a composite index of attention noted 
greater deficits in PDD than AD patients (Beatty et al., 2003). Finally, when attention was 
measured in terms of variability in performance over time in a series of reaction time tasks, 
it showed that 29% of the PDD patients had attentional fluctuations compared to 42% of 
those with DLB (Ballard et al., 2002). From the above findings, it appears that attention is 
impaired in PDD and may fluctuate more than AD. 
4.3 Memory  
Memory, including working memory, long term memory, visuospatial memory and 
procedural learning is significantly impaired in Parkinson’s disease demented patients, but 
the impairment differs from the amnesia seen in patients with Alzheimer’s disease. Memory 
complaint was reported to be the presenting problem in 67% of PDD patients, compared to 
94% with DLB and 100% in AD (Noe et al.,2004).Short term memory has received a little 
attention, although digit span performance which is more an attentional test, does not 
appear to distinguish PDD and AD patients (Starkstein et al.,1996). Learning of new 
information is also impaired, but to a lesser degree than in patients with Alzheimer disease 
(Helkala et al., 1989; Pillon et al., 1991; Stern et al., 1993). Several studies have shown that 
demented patients with Parkinson’s disease have impaired free recall, similar to 
Alzheimer’s disease, but their recognition is better than free recall, which shows that new 
information is stored but not accessed (Helkala et al., 1989; Pillon et al.,1993). A very 
important assumption is that memory in demented patients with Parkinson’s disease was 
related to executive function test scores (Pillon et al., 1993).Therefore, amnesia is not of a 
temporal-limbic type, because patients are able to store information, but is caused by 
difficulty with the accessing of memory traces, which reflects a deficiency in strategy, due to 
a dysexecutive syndrome (Dubois et al., 1997). Both verbal and visual memory are impaired 
in PDD, and the degree of this impairment is probably less than that seen in AD, and 
recognition may be less affected than recall in mild to moderate PDD. 
4.4 Visuospatial dysfunction  
Visuospatial dysfunction was noted in demented patients with Parkinson’s disease and this 
impairment was more severe in demented patients with Parkinson’s disease than with 
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Alzheimer’s disease (but similar to DLB) with approximately similar dementia severity 
(Huber et al.,1989; Stern et al.,1993). Boller et al., (1984) found impairments in 
visuoperceptual and visuomotor tasks, independent of intellectual impairment; however 
patients with larger loss in motor function tended to show the largest visuospatial 
impairment. Visuospatial impairment in PD  is seen especially in more complicated tasks, 
that require planning and strategy, therefore impairments in perceptual motor tasks may be 
in part due to problems in organization of behavioral-executive problems (Stern et al.,1983). 
4.5 Language   
Language is also impaired in patients with PDD, but to a lesser degree than Alzheimer’s 
disease (Cummings et al., 1988; Huber et al., 1989).The domain that is reported to be more 
severe than in patients with Alzheimer’s disease is verbal fluency (Huber et al., 1989; Stern 
et al., 1993). Naming difficulties, decreased information content of spontaneous speech and 
impaired comprehension of complex sentences were described in demented and non 
demented patients with PD, but to a lesser degree than Alzheimer’s disease (Grossman et 
al., 1991; Grossman et al., 1992). 
4.6 Construction and praxis  
Typically, drawing tests are used to assess construction ability and praxis, either copying 
designs or drawing common objects. The clock drawing test is markedly impaired in PDD 
(Emre et al., 2004). It should be noted however, that apraxia is not a common feature of 
PDD, although impaired ideomotor praxis was described (Goldenberg et al., 1986; Huber et 
al., 1989). Impaired verbal fluency and naming difficulties may not reflect an original 
involvement of language function but may be related to dysexecutive syndrome (Grossman 
et al., 1991). 
5. Neuropsychiatric manifestations in PD 
5.1 Depression and anxiety  
Symptoms of depression and anxiety are common in Parkinson’s disease. Approximately 
30-40% of patients with PD have depressive symptoms, with lower prevalence rates in 
population based studies (Leentjens et al 2008; Reijnders et al., 2008). Anxiety also affects up 
to 40% of patients with PD (Leentjens et al., 2008; Menza et al., 1993; Richard 2005). 
Depression and anxiety can be off-period phenomena and respond to antiparkinsonian 
medication (Maricle et al., 1995; Nissenbaum et al., 1987; Siemers et al., 1993; Witjas et al., 
2002).The pathophysiology of these symptoms is complex and probably includes 
dopaminergic, serotonergic and noradrenergic mechanisms. The raphe nuclei and locus 
coeruleus are structures which appear to be involved in depression, early in the course of 
Parkinson’s disease (Braak et al., 2004). There is also clear evidence that dopaminergic 
dysfunction also plays a role. Dopaminergic projections from the ventral tegmentum of the 
midbrain to the medial temporal and orbitofrontal regions are affected in  post mortem 
studies (Torack & Morris, 1988).There is also evidence that limbic 
noradrenergic/dopaminergic pathways are dysfunctional in PD patients with depression 
compared to those without (Remy et al.,2005). The main characteristics of depression are 
low mood and lack of interest or pleasure, one of which is required for a diagnosis of 
depression in most classifications. Other features are altered appetite or sleep, weight 
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change, loss of libido, reduced memory, psychomotor retardation, loss of energy, feelings of 
guilt, and suicidal ideation which can overlap with the symptoms of PD, making diagnosis 
of depression in PD difficult (Gotham et al., 1986; Myslobodsky et al, 2001).The most 
common anxiety disorders in PD are panic attacks which are often noted during off-periods, 
generalized anxiety disorder, simple and social phobias. Outside off-periods, anxiety may 
be part of an underlying depressive disorder (Mondolo et al., 2007). The most commonly 
used diagnostic classification for depression and anxiety is the DSM IV-TR . For screening 
purposes the Hamilton depression scale, Beck depression inventory, Hospital anxiety and 
depression scale and Geriatric depression scale have been shown to be valid in depression of 
PD. However, it’s very important to remember that diagnosis of depression should only be 
made using clinical criteria rather than scales. Several rating scales for anxiety have been 
used in patients with PD, but their validity needs to be assessed further (Leentjens et al., 
2008). Regarding the management of these symptoms, the first important issue, is to 
determine whether the depression and/or anxiety symptoms occur during off-periods. If so, 
then the adjustment of antiparkinsonian medication is required. In most cases with mild 
depression, which are the majority, non-pharmacological intervention is the treatment of 
choice, ranging from counseling - patient education to cognitive-behavioral therapy (Cole & 
Vaughan, 2005).The most useful first step in treatment is the optimization of the existing 
dopaminergic medication. Other pharmacological agents used for depression of PD include 
tricyclic antidepressants, tricyclic-related drugs (trazodone), selective serotonin reuptake 
inhibitors (SSRI), the serotonin and noradrenaline re-uptake inhibitors (SNRI) venlafaxine, 
the selective noradrenaline re-uptake inhibitor reboxetine and the presynaptic alpha2 
adrenoreceptor antagonist mirtazapine. 
5.2 Apathy and fatigue 
Apathy and fatigue are two common non motor manifestations in PD, which contribute to 
disability and are attributed to basal ganglia pathology and disturbances in frontal-
subcortical connections (Dujardin et al., 2007). Reported prevalence for apathy ranges from 
17% to 70% (Isella et al.,2002; Levy et al.,1998;Starkstein et al.,1992) and is influenced by the 
extend of cognitive impairment and depressive symptoms in the sample and the tools used 
(Pluck & Brown,2002; Shulman, 2000). Apathy in the absence of depression occurs in 4-30% 
of cases, whereas reported prevalence for depression in the absence of apathy is 6-28% and 
for combination of apathy-depression is 12-47% (Aarsland et al., 1999; Dujardin et al., 2007; 
Isella et al., 2002). Fatigue is reported in up to 1/3 of patients with PD (Friedmann et al., 
2007), and has a prevalence rate of 32-58%. However, fatigue outcome is influenced by the 
definitions of fatigue and the assessment tool that was used (Alves et al., 2004). Fatigue is 
also associated with depression, cognitive deficits and daytime sleepiness (Rochester et al., 
2004). Apathy refers to a set of behavioral, emotional and cognitive features with reduced 
interest and motivation in goal-directed behaviors (Marin, 1997). The impact of apathy is 
considerable, the patient is inactive and this leads to greater functional decline and disability 
(Aarsland et al., 1999).The role of depression and cognitive impairment in apathy is 
considerable. There are conflicting reports in the literature whether apathy and depression 
combined are more common than apathy without depression or depression without apathy 
(Isella et al., 2002). Fatigue can be classified as peripheral and central (Voon & Lang, 2004). 
Peripheral fatigue is a physiological phenomenon that involves lack of energy associated 
with muscular fatigue, and is measured objectively by decreased force generation or the 
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inability to sustain repetitive movements (Lou et al., 2001). Central fatigue is generally 
described as an abnormal degree of persistent tiredness, weakness or exhaustion that can be 
mental, physical or both in the absence of motor and physical impairment (Lou et al., 2001). 
Physical fatigue represents the sense of physical exhaustion and lack of energy to perform 
physical tasks despite the ability to do so. Mental fatigue refers to the effects experienced 
during and after prolonged periods of demanding cognitive activities that require sustained 
mental efficiency. Fatigue exerts its main effects on quality of life, depression, and disability 
in PD and is the major determinant of work-related disability (Martinez-Martin et al., 2006; 
Zesiewicz et al., 2007). For apathy and fatigue, co-existence of depression and cognitive 
deficits and their overlap with motor signs of PD, contribute to diagnostic challenges. For 
apathy, Marin’s criteria of reduced goal-directed behavior, cognition and emotional 
concomitants of goal-directed behavior are the most widely used (Marin, 1997). 
Distinguishing apathy from depression requires evidence for emotional features such as low 
mood, reduced levels of pleasure, guilt and anxiety in patients with a concurrent depressive 
disorder. A number of fatigue-rating scales have been developed for the general population 
and for specific conditions (Dittner et al.,2004).The Parkinson’s fatigue  scale was developed 
as a disease specific scale and is widely used (Brown et al.,2005).Treatments for both apathy 
and fatigue include illness education to families and patients about depression, fatigue, 
apathy and cognitive decline in PD, behavioral strategies to maximize executive functions 
and use of medication to treat mood disorders and cognitive impairment. It’s very 
important to know that improvement of comorbid conditions may be sufficient to relieve 
apathy and fatigue. Non pharmacological strategies with an individualized daily schedule 
and structure with varied activities and group therapy help to maintain a satisfactory 
activity level. Possible medications include dopamine agonists, psychostimulants, modafinil 
and testosterone (Campbell & Duffy, 1997; Friedman et al., 2007). 
5.3 Hallucinations and psychosis 
The main psychotic symptoms noted in PD include, visuoperceptual symptoms such as 
visual hallucinations, illusions, and delusions. Auditory hallucinations may also occur but 
usually together with visual hallucinations. Psychotic symptoms may be mild or severe, 
occur either in combination or alone, may be accompanied by behavioral disturbances and 
require hospitalization. Psychotic features may affect up to 50% of patients with PD 
(Graham et al.,1997) and when present, tend to be persistent and progressive (Factor et 
al.,2003).The typical visual hallucinations consist of persons, familiar or not, and less often 
animals or objects. They are usually complex and stereotype and often occur in dim light, 
and at night. The neuropsychiatric symptoms in PD tend to cluster into distinct syndromes. 
It’s very important, for the clinician to examine for these phenomena because these 
symptoms are not always reported voluntarily. Some patients may deny or refuse to report 
these symptoms, therefore the clinician should also ask relatives. There are several rating 
scales that can be utilized, although no one is generally accepted. Item 2 of UPDRS subscale 
1 and the neuropsychiatric inventory are most often used. More detailed assessments can be 
made using specific scales such as the Parkinson psychosis rating scale. Psychotic symptoms 
develop from extrinsic and intrinsic factors. It was previously considered that visual 
hallucinations in patients with Parkinson’s disease were caused by dopaminergic 
medications. However, it is now generally accepted that although dopaminergic drugs and 
especially dopamine agonists, can contribute to psychosis, other factors may be more 
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important such as dementia, visuospatial impairment, old age and advanced disease stage. 
It is now well known that psychotic symptoms may occur during the night and are 
associated with sleep disturbances and vivid dreams that may lead to hallucinations. Non 
pharmacological approaches such as information about the nature of these phenomena may 
help. A cognitive approach is also very useful, such as distraction or re-directing attention. 
Improvement of light conditions and visual aids may also help (Diederich et al., 2003). It’s 
crucial to search for general medical conditions such as infection, pain, metabolic disorders, 
dehydration, and recent changes in medication. Concerning the pharmacological approach 
for psychotic symptoms in patients with PD, the reduction of dose or number of drugs may 
reduce these symptoms without worsening the motor condition. For example 
anticholinergic drugs must be withdrawn first. It is better to withdraw selegiline first, 
amantadine and dopamine agonists before changing the L-dopa dose. The drug that is 
recommended is clozapine, which has been shown to reduce visual hallucinations without 
worsening motor features. Other agents such as risperidone and olanzapine are less 
effective and with a higher risk for worsening motor symptoms, cognitive decline and 
confusion (Miyasaki et al., 2006). Finally, initial open label reports on quetiapine were 
promising although two placebo controlled trials were negative. 
5.4 Sleep disorders 
Between 60-98% of patients with Parkinson’s disease experience a sleep disorder (Stacy, 
2002). These disorders include excessive daytime sleepiness, sleep attacks, advanced sleep 
phase syndrome, early morning awakenings and Rapid Eye Movement Sleep Behavior 
Disorder (RBD). Advanced stages of PD are associated with circadian rhythm disruption. 
Only few of these sleep disorders are treatable with dopaminergic therapy, and in fact, 
many are the side effects of treatment. The pathophysiological mechanism of circadian 
rhythm disruption in PD is not fully understood, and is complicated by the concomitant use 
of PD medications, as well as other medications such as antidepressants and stimulants, 
which are known to disrupt sleep architecture. RBD may respond to night-time clonazepam 
or melatonin (Gagnon et al., 2006). Modafinil 200-400mg per day is effective in treatment of 
excessive daytime sleepiness and the sedative effects of anti parkinsonian medications 
(Adler et al., 2003). Finally, nocturnal administration of sodium oxybate has been found to 
improve excessive daytime sleepiness and fatigue in patients with Parkinson’s disease 
(Ondo et al., 2008). 
6. SPECT neuroimaging 
Perfusion brain single photon emission computed tomography (SPECT) provides a well-
established means of studying regional cerebral blood flow (rCBF) which is known to reflect 
cortical function. On the other hand Dopamine Transporter (DAT) SPECT imaging can be 
used as a marker for the degree of loss of dopaminergic nerve endings. It is well known that 
SPECT Neuroimaging can assist in the differential diagnosis of parkinsonian and dementia 
syndromes and DAT SCAN can also be helpful in differentiating tremors resulting from 
damage to the nigrostriatal dopaminergic terminals from those due to essential tremor, 
drug-induced or psychogenic causes (Benamer et al., 2000). SPECT can also be useful in 
monitoring disease progression as well as providing information about the 
pathophysiological process in PD (Burn et al., 2003). Numerous studies during the last 
www.intechopen.com
 
Diagnosis and Treatment of Parkinson’s Disease 
 
58 
decade have attempted to investigate differences and associations between cortical 
perfusion, nigrostriatal dopamine pathway and neuropsychological functions in demented 
and non demented patients with PD. These studies show a tendency towards increased 
hypoperfusion in parietal and temporal lobes in PDD as compared to the non demented PD 
patients (Derejko et al., 2006; Liu et al., 1992; Matsui et al., 2005).There are also conflicting 
results in the literature regarding PD patients with MCI ranging from either no difference 
compared to controls (Sawada et al., 1992; Spampinato et al.,1991) or to hypoperfusion in the 
parietal (Wallin et al.,2007) and frontal areas (Antonini et al.,2001; Firbank et al.,2005; 
Paschali et al.,2009). Regarding rCBF and neuropsychological functions in different stages of 
PD, as dopaminergic nerve endings degenerate in PD there is progressive cortical 
hypoperfusion affecting mainly the frontal lobes in the early stages, extending to the parietal 
and temporal lobes in the late stages of Parkinson’s disease. In parallel, neuropsychological 
performance gradually deteriorates as the disease progresses (Paschali et al., 2010). 
7. Studies investigating correlations between cortical perfusion, nigrostriatal 
dopamine pathway and neuropsychological functions in PD patients 
A study using 18F fluorodeoxyglucose positron emission tomography and 
neuropsychological tests identified a cognitive network associated with hypermetabolism of 
the medial and anterior temporal lobe, pons and cerebellum, concomitant to metabolic 
decreases in the parieto-occipital cortex that was related to mnemonic and visuospatial 
deficits in non-demented PD patients (Mentis, et al., 2002)  
 Another FDG-PET study in non-demented PD patients revealed a correlation of 
performance on tests of memory, visuospatial function and perceptual motor speed with a 
cognitive pattern characterized by metabolic reductions in frontal and parietal association 
areas and relative increases in the cerebellar vermis and dentate nuclei which was not 
altered by routine antiparkinsonian treatment (Huang, et al., 2007)  
Marie et al. (1995) found verbal working memory performance to correlate positively with 
resting brain glucose metabolism in the dorsolateral prefrontal cortex. The same group in 
another study reported a correlation between working memory functions and striatal 
uptake of [11C]-S-nomifensine, a radioligand for the presynaptic dopamine and 
noradrenaline transporters (Marie et al., 1999). Holthoff-Deto et al. (1997) found that deficits 
in paired associate learning in a subgroup of moderately to severe PD patients was shown to 
correlate with [18F] dopa binding in the caudate nucleus. Further, Muller et al. (2000) found 
impaired prefrontal cognitive functions and preserved short-term memory, in a combined 
neuropsychological and neuroimaging study of twenty PD patients without dementia or 
depression. DAT density in the putamen as evaluated by [123I]β-CIT SPECT was related to 
the severity of motor deficits and cognitive functions correlated with the integrity of both 
striatal compartments. The authors concluded that the striatum is part of a neuronal 
network mediating prefrontal cognitive tasks. Another study by Antonini et al (2001) found 
significant decrements in frontal lobe perfusion in PD patients without cognitive 
impairment. This data is consistent with the presence of reduced frontal lobe activity and 
may be related to reduced dopaminergic input from the basal ganglia to this region. 
Conversely, in the demented group, the study found more diffused cortical perfusion 
defects involving the temporal and parietal cortex. This finding is consistent with the 
neuropathological finding that neocortical cholinergic activity is depleted in patients with 
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PDD. In a longitudinal of 44 consecutive patients at an early stage of PD by Dujardin and 
colleagues (2004), 3 years after diagnosis, a proportion of patients showed reduced overall 
cognitive efficiency, a subcorticofrontal syndrome and more severe motor symptoms as 
measured by the motor UPDRS score. At the time of diagnosis, best predictors of this 
progression were specific cognitive scores, such as the interference index from the Stroop 
word-colour test and the number of animal nouns named on the semantic word fluency 
task, as well as more general variables such as the educational level and the MMSE score. 
Other indices that contributed to a lesser extent were specific cognitive scores, such as 
delayed recall in the Grober&Buschke test, the Mattis DRS score and SPECT measurements 
such as the left Temporal-Insular, Left Temporal-Parietal-Occipital, Right Temporal-Insular 
and Left lenticular nucleus regional cerebral blood flow.  
In another study, Osaki et al (2005) identified regions with a reduced regional cerebral blood 
flow using the 3D-Stereotactic Surface Projection [123I] IMP-SPECT in cases for which the 
original diagnosis was PD. Multiple hypoperfusion areas were also observed in this 
analysis. There were significant correlations between clinical manifestations and regional 
hypoperfusion, namely between the presence of dementia and the bilateral posterior 
cingulated areas, and between fluctuating cognition and the bilateral parietal association 
areas, medial parietal lobes and dorsal occipital lobes. Derejko and colleagues (2006) 
observed significantly greater bilateral temporal and left parietal decrease of regional 
cerebral blood flow in PDD patients as compared to a group without cognitive impairment. 
This pattern of perfusion deficits described as ‘a posterior’ type of hypoperfusion resembles 
the one mostly described in Alzheimer’s disease, except that defects were often unilateral, 
whereas predominantly bilateral defects are seen in AD. Hypoperfusion within the left 
temporal cortex with additional hyperperfusion in the ipsilateral thalamus were the most 
significant factors associated with cognitive decline and dementia.  
In a study by Firbank et al (2005) the aim was to monitor perfusion changes over a one-
year period in subjects with PDD compared to a group with DLB, and also healthy 
controls, and to relate any perfusion changes to cognitive impairment or motor 
functioning. The authors hypothesized that cortical (parieto-occipital) changes would be 
associated with worsening of cognitive function, and basal ganglia changes with 
progression of motor features. The main finding of this study was a bilateral increase in 
perfusion in the putamen of DLB patients over a year, and a correlation between 
increased striatal perfusion and worsening motor symptoms in both PDD and DLB. The 
authors postulate, that this is associated with continued dopaminergic degeneration, a 
process which may appear more pronounced in DLB because of the relatively more intact 
nigrostriatal dopaminergic system at the baseline scan compared to PDD, perhaps due to 
the shorter duration of Parkinsonism. In another study by Colloby et al (2005), the authors 
investigated the progression of dopaminergic degeneration in patients with DLB, PD and 
PDD and healthy controls using serial SPECT imaging with 123I-FP-CIT, a marker for 
dopamine transport, using a semi-automated region of interest approach. This study 
found that serial FP-CIT over 1 year demonstrated progressive dopaminergic loss 
compared with controls in DLB, PD and PDD, and showed that serial dopaminergic 
SPECT may be useful in monitoring disease progression in DLB, PD as well as PDD. 
Dementia severity and motor impairment were predictors of percentage decline, 
suggesting that dopaminergic loss may play an important role in the development of 
cognitive as well as motor features.  
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In another study comparing SPECT findings between patients with PD and DLB by Chang 
et al (2008), significant perfusion differences in bilateral temporal areas were noted between 
the DLB and PD groups, with a lower perfusion index in the DLB group. On the other hand, 
Rossi and colleagues (2009) concluded that neither FP-CIT nor ECD-SPECT investigations 
were able to discriminate between DLB and PDD in vivo. These findings might support the 
theory that PDD and DLB share clinical and neurobiological characteristics within a 
Parkinson-Dementia spectrum. Moreover, the perfusional cortical pattern of both PDD and 
DLB is unrelated to dopaminergic impairment evaluated either clinically or by means of 123I-
FP-CIT SPECT and it may be due to different neurochemical systems impairment.  Wallin et 
al (2007) note in their study that reductions of cortical blood flow in PD patients with 
cognitive impairment indicate cortical brain dysfunction. In the PDD group, the regional 
cerebral blood flow reductions were extensive and bilaterally symmetric, involving both 
anterior and posterior brain regions. In the PD-MCI group, individual variations were seen, 
but a nonsignificant reduction in the posterior brain regions was the most prominent 
finding. These findings suggest once more that there is an associatiom between the degree of 
cognitive impairment and the magnitude of cortical brain dysfunction in PD patients. In 
addition, hypoperfusion in the left inferior parietal lobule and supramarginal gyrus has 
been reported in a small group of PD-MCI patients with low performance in the frontal 
assessment battery (Matsui et al., 2006).  
In another study by Nobili et al (2009), that investigated cortical dysfunction in PD-MCI 
patients, the authors found a posterior parietal-occipital hypoperfusion pattern in PD-MCI, 
maximally expressed in the comparison with both healthy subjects and common amnestic 
MCI patients, and more slightly in comparison with cognitively unimpaired PD patients. 
These findings are consistent with the hypothesis that PD patients with MCI of the amnestic 
type may be at high risk of developing PDD, by sharing a similar posterior pattern of 
cortical dysfunction. Finally, a recent study by Nobili and colleagues (2010) showed that the 
associations between nigrostriatal and cognitive functions are different for the nigro-caudate 
and for the nigro-putaminal endings in PD, whereas in the control group nigrostriatal and 
cognitive functions are not correlated. In de novo PD patients, the nigro-caudate 
dysfunction is significantly correlated to executive functions. This result is in keeping with 
other studies, highlighting the relationships between nigro-caudate impairment and 
executive dysfunction in PD. In this study, the motor severity of the disease was not 
correlated to executive functions and just marginally to caudate uptake.  
A PET study using an alpha4beta2*-nAChR-specific radioligand provided in vivo evidence 
that there is a broad reduction of alpha4beta2*-nAChR availability in patients with PD 
without clinically manifest dementia or depression compared with healthy volunteers. 
Reduced alpha4beta2*-nAChR binding in patients with PD within the subcortical and 
cortical regions was associated with the severity of mild cognitive or depressive symptoms 
(Meyer et al., 2009)  
8. Studies contributing to the neuropsychological and SPECT neuroimaging 
literature in PD conducted at the University of Patras Medical School  
In our first study (Paschali et al., 2009) we examined relationships between 
neuropsychological functions and brain single photon emission computed tomography 
(SPECT) regional cerebral blood flow observed at presurgical evaluation for deep brain 
stimulation (DBS) of the subthalamic nucleus (STN) in advanced PD patients. Twenty 
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advanced non-demented PD patients, candidates for DBS surgery, underwent perfusion 
brain SPECT study and neuropsychological assessment prior to surgery (range 30-50 days). 
Patients were further assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS) 
and Hoehn and Yahr (H&Y) scale. During all assessments patients were on standard 
medication. Neurogam Software, which permits voxel by voxel analysis, was used to 
compare the brain perfusion of PD patients with a normal database adjusted for sex and age. 
Neuropsychological scores were compared to age, education and sex- adjusted normative 
databases. Our results indicated that the distribution of rCBF showed significant differences 
when compared to an age and sex-adjusted normative database. We found impaired blood 
flow in 17 (85%) of our patients in the left prefrontal lobe, in 14 (70%) in the right prefrontal 
lobe and in 11 (55%) in the left frontal and right parietal lobes. Neuropsychological testing 
revealed that 18 (90%) of our patients had significant impairments in measures of executive 
functions (set-shifting) and 15 (75%) in response inhibition. Furthermore we found 
significant correlations between measures of visual attention, executive functions and the 
right frontal lobe region. The presence of widespread blood flow reduction was observed 
mainly in the frontal lobes of non-demented patients with advanced PD. Furthermore, 
performance on specific cognitive measures was highly related to perfusion brain SPECT 
findings. Frontal lobe dysfunctions in PD have also been reported from other studies as 
mentioned above. In a recent review by Zgaljardic et al., (2003), frontostriatal circuit 
impairments in PD were described and it was suggested that the anterior cingulated cortex 
was related to conflict monitoring, motivation, response initiation and apathy. Moreover, 
they showed that the dorsolateral prefrontal cortex was related to working memory, set 
shifting, conditioned associate learning, set maintenance and memory retrieval, while the 
orbitofrontal cortex was related to stimulus-driven behavior, disinhibition, and impulse 
control.  
In our second study (Paschali et al., 2010), we investigated differences and associations 
between cortical perfusion, nigrostriatal dopamine pathway and neuropsychological 
functions in different stages of PD. We recruited 53 non-demented PD patients divided into 
four groups according to the Hoehn and Yahr staging system and 20 healthy controls who 
were used in the comparison of the neuropsychological findings. Each patient underwent 
two separate brain single photon emission computed tomography (SPECT) studies 
(perfusion and dopamine transporter binding) as well as neuropsychological evaluation. 
Perfusion images of each patient were quantified and compared with a normative database 
provided by the Neurogam software manufacturers. Mean values obtained from the cortical 
areas and neuropsychological measures in the different groups were also compared by 
analysis of covariance (ANCOVA) controlling for disease duration and educational level. 
We found cognitive deficits especially in the late PD stages (HY 3, 4, 5) compared to the 
early stages (HY 1, 2) and associations between cognitive decrements and cortical perfusion 
deterioration mainly in the frontal and posterior cortical areas. Compared with controls, PD 
patients showed impairments of cognition and cerebral perfusion that increased with 
clinical severity. Furthermore, we found a significant correlation between the performance 
on the phonemic fluency task and regional cerebral blood flow in the left frontal lobe. 
Dopamine transporter binding in the left caudate nucleus significantly correlated with blood 
flow in the left dorsolateral prefrontal cortex, but not with measures of executive functions.  
We reached the conclusion that there are significant cognitive and perfusion deficits 
associated with PD progression, implying a multifactorial neurodegeneration process apart 
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from dopamine depletion in the substantia nigra pars compacta. As dopaminergic nerve 
endings degenerate in PD, there is a progressive cortical hypoperfusion affecting mainly the 
frontal lobes in the early stages, extending to the parietal and temporal lobes in the late 
stages of the disease. In parallel, neuropsychological performance gradually deteriorates as 
the disease progresses. The findings of this study support the multifactorial degeneration 
process in PD, as the degeneration of the nigrosrtiatal pathway of dopamine alone, cannot 
explain the perfusion and cognitive deficits in PD progression 
9. Conclusions 
DAT reduction correlates with dopamine neuron loss in the substantia nigra and striatum 
which is characteristic for PD. Neuropsychological deficits in the disease cannot be 
explained by dopamine loss alone as indicated by neuroimaging studies using DAT 
radiotracers. Thus further evidence is provided through these studies that additional 
changes occur in the brains of PD patients. Studies of regional cerebral blood flow in PD as 
an indicator of cognitive impairment show a more diffuse reduction in cortical metabolism 
as a result of disease progression and transition to dementia.  On the other hand the 
identification of certain metabolic brain networks associated with cognitive functions in 
non-demented PD patients may provide a tool in clinical trials targeting the progression of 
non-motor manifestations of the disease and the possible efficacy of new drugs to be tested 
in PD. The differential diagnosis between PDD and other parkinsonian syndromes with 
dementia may be assisted but is not yet clearly established by PET and SPECT. The recent 
development of novel radioligands for use in PET studies point to the role of other 
neurotransmitter deficits such as the cholinergic deficit in cognitive impairment in PD. 
SPECT neuroimaging may therefore be useful not only in understanding the 
pathophysiology of the disease and cognitive impairment but also for clinical monitoring in 
research studies in PD.  
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